Skip to main content

Table 3 Application of the developed HPLC method on different plasma samples

From: Homogeneous liquid–liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma

 

Amount added

(ng/mL)

Amount found

(ng/mL)

%Found

 ± RSD

Plasma 1

 NIRMA

5000

5241

104.82 ± 5.09

15,000

14,748

98.32 ± 1.23

 RITONA

5000

5177

103.53 ± 3.37

15,000

15,537

103.58 ± 4.12

Plasma 2

 NIRMA

5000

4910

98.19 ± 3.12

15,000

16,368

109.12 ± 2.98

 RITONA

5000

4995

99.90 ± 3.67

15,000

15,923

106.15 ± 1.4

Plasma 3

 NIRMA

5000

4588

91.75 ± 2.16

15,000

14,373

95.82 ± 3.41

 RITONA

5000

5359

107.18 ± 4.58

15,000

14,703

98.02 ± 4.91